Full-Time

Europe TIDES Discovery Business Development Head

Deadline 10/14/27
WuXi AppTec

WuXi AppTec

1,001-5,000 employees

Global contract research, development, manufacturing organization

No salary listed

United Kingdom

In Person

Canada Citizenship Required

Category
Business & Strategy (1)
Required Skills
Lead Generation
Salesforce
Requirements
  • 15 + years of experience at a pharmaceutical company, biotech or Contract Research Organization (CRO) or equivalent with an established track record in leading a team.
  • Strong scientific expertise and new drug development insight
  • A professional degree in science or pharmaceuticals - M.S. required, PhD preferred
  • At least 5 years of experience leading highly professional multi-national team including senior members
  • Must be a self-starter, self-motivated, highly flexible, with excellent communication skills (verbal, written, and presentation skills). Must be organized and detail oriented.
  • Must have a proven track record of meeting or exceeding sales growth objectives and/or simultaneously managing several projects and timelines.
  • Ability to perform within a professional environment and use judgment as dictated by the complexity of a situation.
  • Experience with CRM (Customer Relationship Management) software (i.e. Sales Force and/or Microsoft Dynamics/CRM) is preferred
Responsibilities
  • Leads a team to prospect for oligonucleotide and peptide new drug discovery companies that would benefit from TIDES CRDMO model.
  • Manages strategic relationships with selected key accounts within the TIDES Discovery business in Europe. Attends conferences and meetings to present TIDES services to prospective and existing clients via email, phone, and web-conferencing systems.
  • Acts upon, refers to, and follows up on leads from both sales and marketing campaigns.
  • Increase awareness of TIDES’s marketing initiatives, including scheduling meetings for tradeshows and driving registrations for webinars and seminars.
  • Maintains knowledge of industry trends, funding, regulatory influence, mergers and acquisitions, in-out licensing of products/technologies, government/private grants and contacts, new drug development and approvals, related patent grants and notifications, market growth of small, med, and large-cap companies.
  • Develop a social network of industry-related contacts via LinkedIn and other social networking platforms.
  • Strategizes quarterly business development plans and benchmarks performance for continued success.
  • Travel to local client meetings and tradeshows to assist the Business Development team as required.
  • Proposes new ideas and strategies to increase performance and drive personal and team goals.
  • Documents information in Client Relationship Management (CRM), including contacts, pre-screened/qualified leads, and new account information as required.
  • Stays current on competitors and competitive strategies and provides input needed for the development of future services and products
  • Builds strong internal relationships across functions
  • Key BD liaison along with senior leadership during crisis management; create business solutions and engage in business continuity planning as well as execution when the need arises.
  • Ensure successful partner visits to China, Europe, and other new potential TIDES entities worldwide
Desired Qualifications
  • Experience with international regulatory affairs in Oligonucleotide and Peptide CDMO
  • Fluent in German and English
  • Experience in leading business development for European region specifically in oligonucleotide and peptide CDMO
  • Knowledge of WuXi group structure and cross-functional coordination

What WuXi AppTec does: It provides a global, integrated open-access platform for contract research, development, and manufacturing services (CRDMO) to the pharmaceutical, biotechnology, and medical device industries. How its products work: Clients access a broad portfolio of capabilities—laboratory testing, process development, and manufacturing—across the full product lifecycle, from discovery and preclinical work to clinical and commercial production, often supported by strategic acquisitions to extend reach. How it differs from competitors: It combines extensive geographic reach with a wide, end-to-end service portfolio in one platform, rather than focusing on a narrow stage or region. What its goal is: To help innovators bring new medicines and healthcare products to market faster and with high quality.

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

Huangpu, China

Founded

2000

Simplify Jobs

Simplify's Take

What believers are saying

  • Q1 2026 revenue surged 28.8% to RMB 12.44 billion with 72% adjusted profit growth.
  • $510 million Delaware facility occupies 1.74 million sq ft by August 2026.
  • Ninth Frost & Sullivan CRDMO Company of the Year Award in 2025 affirms leadership.

What critics are saying

  • BIOSECURE Act bans US federal contracts from 2026, cutting 62% US revenue.
  • PLA-linked genetic testing triggers US blacklisting and client exodus like Pfizer.
  • Lonza undercuts pricing, eroding WuXi Chemistry's 43.7% Q1 2026 growth.

What makes WuXi AppTec unique

  • WuXi AppTec's end-to-end CRDMO platform spans discovery to commercialization across small molecules and biologics.
  • Global network of 20 sites serves 6,000 customers in 30+ countries from Asia, US, and Europe.
  • Open-access model founded in 2000 lowers R&D barriers for pharma and biotech innovators.

Help us improve and share your feedback! Did you find this helpful?

Your Connections

People at WuXi AppTec who can refer or advise you

Benefits

Remote Work Options

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

-1%

2 year growth

0%
Yahoo Finance
Mar 23rd, 2026
WuXi AppTec reports record $6.2B revenue, 41.3% profit surge in 2025

WuXi AppTec, a global pharmaceutical contract research, development and manufacturing organisation, reported record 2025 results, beating full-year guidance. Total revenue reached RMB 45.46 billion, up 15.8% year-on-year, whilst revenue from continuing operations rose 21.4% to RMB 43.42 billion. Adjusted non-IFRS net profit increased 41.3% to RMB 14.96 billion, with the profit margin rising 5.9 percentage points to 32.9%. The company's backlog for continuing operations grew 28.8% to RMB 58.00 billion. The firm added 839 new molecules to its small molecule development and manufacturing pipeline in 2025, bringing the total to 3,452. WuXi AppTec achieved its first MSCI AAA and CDP Climate Change A ratings during the year.

EIN Presswire
Dec 17th, 2025
Yale and Princeton-funded Chinese firm buys stake in Shanghai biotech linked to military

A Chinese investment firm funded by Yale and Princeton universities has purchased a stake in WuXi AppTec, a Shanghai biotech company that US lawmakers say operates genetic testing centres in coordination with China's People's Liberation Army. The company has faced accusations of assisting Beijing in identifying Uyghur Muslims in Xinjiang. Last year, American legislators warned about WuXi AppTec's military connections and operations. The investment highlights concerns about elite US institutions indirectly funding Chinese companies with military ties through their endowment investments. Neither the investment firm nor the universities have publicly commented on the transaction or its implications for national security.

PR Newswire
Dec 10th, 2025
D3 Bio raises $108M Series B to advance global Phase III trials for cancer drug elisrasib

D3 Bio, a clinical-stage biotechnology company focused on oncology therapeutics, has raised $108 million in a Series B financing round. The round was backed by IDG Capital and SongQing Capital, with participation from existing investors including WuXi AppTec's Corporate Venture Fund, Temasek, HSG, MPCi and Medicxi. The funding will primarily support D3 Bio's planned global Phase III pivotal programme for elisrasib (D3S-001), its lead asset targeting KRAS G12C-mutant cancers. The trials will evaluate elisrasib as monotherapy and in combination treatments across the United States, China and the European Union to facilitate global regulatory submissions. The proceeds will also advance D3 Bio's pipeline of targeted and immuno-oncology programmes with first-in-class or best-in-class potential.

PR Newswire
Apr 1st, 2025
Wuxi Apptec'S Changzhou And Taixing Api Sites Successfully Pass Fda Inspections

SHANGHAI, March 31, 2025 /PRNewswire/ -- WuXi AppTec, a global company that provides a broad portfolio of RD and manufacturing services to enable companies in the pharmaceutical and life sciences industry, today announced that its Active Pharmaceutical Ingredient (API) manufacturing sites at Changzhou and Taixing in Jiangsu province of China, successfully passed U.S. Food and Drug Administration (FDA) inspections back-to-back in March — both without a single observation and with no Form 483 issued. These achievements further demonstrate WuXi AppTec's unwavering commitment to upholding the highest quality standards and to supporting global healthcare innovators in reliably delivering needed therapies to patients worldwide

intelligence360
Feb 17th, 2025
Wuxi Apptec To Spend $510 Million To Occupy 1.74 Million Square Feet Of Space In Middletown Delaware.

WuXi AppTec to spend $510 Million to occupy 1.74 Million square feet of space in Middletown Delaware. WuXi AppTec to spend $510 Million to occupy 1.74 Million square feet of space in Middletown Delaware.Middletown, Delaware — According to state and local development sources, WuXi AppTec plans to invest $510,000,000.00 to build out 1,740,000 square feet of new space in Middletown. The company plans to occupy the new space in Middletown, on or about August 1, 2026. According to the company website As a global company with operations across Asia, Europe, and North America, WuXi AppTec provides a broad portfolio of RD and manufacturing services that enable the global pharmaceutical and life sciences industry to advance discoveries and deliver groundbreaking treatments to patients. Through its unique business models, WuXi AppTecs integrated, end-to-end services include chemistry drug CRDMO (Contract Research, Development and Manufacturing Organization), biology discovery, preclinical testing and clinical research services, advanced therapies CTDMO (Contract Testing, Development and Manufacturing Organization), helping customers improve the productivity of advancing healthcare products through cost-effective and efficient solutions. WuXi AppTec received an AA ESG rating from MSCI for the third consecutive year in 2023 and its open-access platform is enabling more than 6,000 customers from over 30 countries to improve the health of those in need and to realize the vision that every drug can be made and every disease can be treated.To learn more about WuXi AppTec, visit http://www.wuxiapptec.com/Company Contact:Rick Connell, [email protected]://www.linkedin.com/in/rick-connell/857-413-2800SOURCE: http://www.intelligence360.ioCopyright (c) 2025 SI360 Inc